|
Male sex
|
49 (68)
|
17 (89.5)
|
0.06
|
|
Age, years*
|
66.5 (24–88)
|
67 (41–84)
|
0.59
|
|
APACHE II*
|
11 (2–28)
|
13.5 (6–24)
|
0.05
|
|
Co-morbidities, n (%):
|
|
Malignancy
|
11 (15.3)
|
3 (15.8)
|
1
|
|
Cardiovascular
|
21 (29.2)
|
5 (26.3)
|
1
|
|
Pulmonary
|
24 (33.3)
|
9 (47,4)
|
0,26
|
|
Diabetes Mellitus
|
20 (27.8)
|
1 (5.3)
|
0.06
|
|
Urogenitala
|
11 (15.3)
|
3 (15.8)
|
1
|
|
Hepatic
|
8 (11.1)
|
8 (0)
|
0.2
|
|
Haematologicalb
|
9 (12.5)
|
3 (15.8)
|
0.7
|
|
Neurologicalc
|
16 (22.2)
|
2 (10.5)
|
0.34
|
|
Charlson*
|
4.5 (0–10)
|
4 (1–9)
|
0.73
|
|
McCabe**
|
1.4 ± 0.6
|
1.7 ± 0.7
|
0.11
|
|
Severe sepsis, n (%)
|
49 (68.1)
|
9 (47.4)
|
0.095
|
|
Shock
|
6 (8.3)
|
1 (5.3)
|
0.65
|
|
Patients with CKD at baseline
|
16 (22.2)
|
3 (15.8)
|
0.53
|
|
Department of hospitalization:
|
|
Medical
|
38 (52.8)
|
6 (31.6)
|
0.16
|
|
Surgical
|
23 (32)
|
9 (47.4)
| |
|
ICU2
|
11 (15.3)
|
4 (21.1)
| |
|
Admission diagnosis category:
|
|
Infection
|
19 (26.4)
|
7 (36.8)
| |
|
Other-medical
|
30 (41.7)
|
5 (26.3)
| |
|
Other-surgical
|
23 (3.9)
|
7 (36.8)
|
0.45
|
|
CMS daily dose (millions IU)**
|
5.3 ± 2.3
|
6.2 ± 2.1
|
0.094
|
|
CMS total dose (millions IU)**
|
105.91 ± 88.9
|
141.2 ± 129.5
|
0.45
|
|
CMS duration of treatment, days**
|
20.66 ± 16.1
|
22.6 ± 18.5
|
0.81
|
|
Combined treatment, n (%)
|
35 (48.6)
|
11 (57.9)
|
0.47
|
|
Css (mg/mL)**
|
1.49 ± 1.4
|
2.42 ± 1.49
|
0.01
|
|
Css > 1.25 (mg/mL), n (%)
|
32 (45.1)
|
14 (73.7)
|
0.027
|
|
Css/MIC**
|
3.13 ± 2.9
|
4.61 ± 2.86
|
0.03
|
|
AKI at day 7, n (%)
|
18 (25)
|
12 (63.2)
|
0.002
|
|
AKI at the EOT, n (%)
|
33 (45.8)
|
16 (84.2)
|
0.003
|
|
Length of stay, days**
|
69.16 ± 59.5
|
70.8 ± 39.1
|
0.19
|
